|
Descriere produs:
Tablete pentru tratamentul hipertiroidismului HESKA ThyroMedâ„¢ Chewable Tablets Benefits and Features
- Increase client compliance — Chewable, palatable tablet makes it easier for pet owners to administer daily.
- Easy dosing — Available in 8 strengths and 2
sizes � 1,000-count for clinic dispensing, or 180-count with
child-proof cap for direct sale to clients.
- Case management support — Talk to one of Heska's DVMs for case consultation at 1-800-GO HESKA.
Dosage:
0.1 mg - 0.8 mg (0.1 mg increments)
Count:
180 (child-proof cap) and 1,000
Expiration:
3 years from date of manufactureCaution:
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Description:
Each ThyroMedâ„¢ Chewable Tablet (Levothyroxine Sodium, USP) provides synthetic crystalline levothyroxine sodium (L-thyroxine).
The structural formula for levothyroxine sodium is:
Levothyroxine sodium action:
Levothyroxine sodium acts, as does endogenous thyroxine, to stimulate
metabolism, growth, development and differentiation of tissues. It
increases the rate of energy exchange and increases the maturation rate
of the epiphyses. Levothyroxine sodium is absorbed rapidly from the
gastrointestinal tract after oral administration. Following absorption,
the compound becomes bound to the serum alpha globulin fraction. For
purposes of comparison, 0.1 mg of levothyroxine sodium elicits a
clinical response approximately equal to that produced by one grain (65
mg) of desiccated thyroid.
Indications:
Provides thyroid replacement therapy in all conditions of inadequate
production of thyroid hormones. Hypothyroidism is the generalized
metabolic disease resulting from deficiency of the thyroid hormones
levothyroxine (T4) and liothyronine (T3). â„¢
Chewable Tablets (Levothyroxine Sodium, USP) will provide levothyroxine
(T4) as a substrate for the physiologic deiodination to liothyronine
(T3). Administration of levothyroxine sodium alone will result in
complete physiologic thyroid replacement.
Canine hypothyroidism is usually primary, i.e. due to atrophy of the
thyroid gland. In the majority of cases the atrophy is associated with
lymphocytic thyroiditis and in the remainder it is noninflammatory and
as of yet unknown etiology. Less than 10 percent of cases of
hypothyroidism are secondary, i.e. due to deficiency of thyroid
stimulating hormone (TSH). TSH deficiency may occur as a component of
congenital hypopituitarism or as an acquired disorder in adult dogs, in
which case it is invariably due to the growth of a pituitary tumor.
Hypothyroidism in the dog:
Hypothyroidism usually occurs in middle-aged and older dogs although
the condition will sometimes be seen in younger dogs of the larger
breeds. Neutered animals of either sex are also frequently affected,
regardless of age. The following may be clinical manifestations of
hypothyroidism in dogs:
Dermatological:
Atrophy of the epidermis, thickening of the dermis
Surface and follicular hyperkeratosis, pigmentation
Puffy face, blepharoptosis, tragic expression
Dry, coarse, sparse haircoat, slow regrowth after clipping
Retarded turnover of hair (carpet coat of boxers)
Metabolic:
Lethargy, lack of endurance, increased sleeping Reduced interest, alertness and excitability
Slow heart rate, weak apex beat and pulse, low voltage on ECG
Preference for warmth, low body temperature, cool skin
Increased body weight
Musculoskeletal:
Stiff and slow movements, dragging of the front feet
Head tilt, disturbed balance, unilateral facial paralysis
Reproductive:
Shortening or absence of estrus, lack of libido
Gastrointestinal:
Dry feces, occasional diarrhea
Clinical pathological:
Hypercholesterolemia
Normochromic, normocytic anemia
Elevated serum creatinine phosphokinase
Contraindications:Levothyroxine sodium
therapy is contraindicated in thyrotoxicosis, acute myocardial
infarction and uncorrected adrenal insufficiency. Use in pregnant
bitches has not been evaluated.
Precautions:
The effects of levothyroxine sodium therapy are slow to manifest.
Overdosage of any thyroid drug may produce the signs and symptoms of
thyrotoxicosis including, but not limited to: polydipsia, polyuria,
polyphagia, reduced heat tolerance and hyperactivity or personality
change. Administer with caution to animals with clinically significant
heart disease, hypertension, or other complications for which a sharply
increased metabolic rate might prove hazardous.
The material safety data sheet (MSDS) contains more detailed
occupational safety information. For technical service, to report an
adverse event or to obtain a copy of the MSDS, call 1-888-437-5287.
Adverse reactions:
There are no particular adverse reactions associated with levothyroxine sodium therapy at the
recommended dosage levels. Overdosage will result in the signs of thyrotoxicosis listed above under precautions.
Dosage:
The initial recommended dose of levothyroxine is 0.1 mg/10 lb (4.5 kg)
body weight twice daily. Dosage is then adjusted by monitoring the
post-pill blood level of thyroid hormone in the dog every four weeks
until an adequate maintenance dose is established. The usual
maintenance dose is 0.1 mg/10 lb (4.5 kg) once daily.
Administration:
â„¢ Chewable Tablets may be given orally to dogs
as a treat, or crumbled over their food at the veterinarian-prescribed
dose. If crumbled over food, consumption should be monitored.
How supplied:
â„¢ Chewable Tablets are available in 0.1 mg, 0.2
mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg,
0.7 mg and 0.8 mg strength chewable tablets. Tablets are bilaterally
scored. The tablets are packaged in bottles of 180 tablets (with
childproof caps) and 1,000 tablets.
Storage:
Store at controlled room temperature; 150C to 300CÂ and protect from light.
|
mareste imaginea
